MA-EVERBRIDGE
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management and enterprise safety software applications to help keep people safe and businesses running faster, has announced the completion of its acquisition of Unified Messaging Systems ASA ("UMS"). Based in Oslo, Norway, UMS provides a unique countrywide mobile population alerting system globally and is also one of the leading critical communications providers in Europe. By uniting UMS’s proven mobile alerting, crisis management, and notification applications with Everbridge’s market-leading Critical Event Management (CEM) software platform, the acquisition creates an unparalleled set of solutions to help customers assess threats, initiate and manage incidents, and notify stakeholders from a local neighborhood or building to a countrywide level, and across the globe.
UMS’s Population Alerting System (PAS) provides 2-way SMS broadcast capabilities to an entire mobile population. To accomplish this, UMS has the unique ability to message the mobile phones of anyone connected to a carrier’s cell towers. The company also provides Location-Based Alerting technology which enables municipalities to geographically pinpoint where to send notifications within a region. This capability is equally applicable for national and global companies who want to reach local and traveling employees, automating the alert by preferred language. UMS’s PAS systems are deployed in a number of countries, providing countrywide alerting to Sweden, Norway, the Netherlands, the Bahamas, Singapore, Greece, and Cambodia, as well as in the city of Kiev, and some of the largest states in India.
As one of the leading mass notification providers internationally, UMS significantly increases Everbridge’s international reach. UMS supports, for example, over 1,200 customers in Northern Europe and reaches over 500 million people globally via population alerting. Its crisis and emergency management product Previstar is used for planning and resource management purposes by major public safety agencies in such places as Virginia, Georgia, Massachusetts, West Bengal in India, as well as by the U.S. Navy. Previstar will considerably enhance Everbridge’s crisis management capabilities.
“We are thrilled to welcome UMS to the Everbridge family, accelerating our international growth and creating the most comprehensive Critical Event Management platform for business, state and local government, and now entire countries,” said Jaime Ellertson, CEO of Everbridge. “UMS provides Everbridge with a passionate and customer-focused team of experts, differentiated technology, and a shared mission to keep people safe and businesses running during a critical event.”
Together, Everbridge and UMS form a global team of over 700 employees dedicated to delivering innovative, differentiated solutions for critical event management. The collective entity expands Everbridge’s international expertise in business continuity, emergency response, and critical event planning, while providing UMS customers access to Everbridge’s Critical Event Management platform for improved messaging scale and delivery across the world.
“Everbridge’s extensive technical capabilities, the breadth of its offerings, and the experience of its global team made for a natural fit with UMS,” said Espen Gylvik, Chief Executive Officer, UMS. “We look forward to aligning with the market leader to provide critical services and innovative communication solutions to make a significant difference in people’s lives.”
The acquisition values the total share capital of UMS at approximately NOK 268 million, or approximately USD $33.6 million.
About Everbridge
Everbridge,
Inc.
(NASDAQ: EVBG) is a global software company that provides
enterprise software applications that automate and accelerate
organizations’ operational response to critical events in order to keep
people safe and businesses running faster. During public safety threats
such as active shooter situations, terrorist attacks or severe weather
conditions, as well as critical business events such as IT outages,
cyber-attacks or other incidents such as product recalls or supply-chain
interruptions, over 3,700 global customers rely on the company’s
SaaS-based platform to quickly and reliably aggregate and assess threat
data, locate people at risk and responders able to assist, automate the
execution of pre-defined communications processes, and track progress on
executing response plans. The company’s platform sent over 2 billion
messages in 2017 and offers the ability to reach more than 200 countries
and territories with secure delivery to over 100 different communication
devices. The company’s critical communications and enterprise safety
applications include Mass Notification, Incident Management, Safety
Connection™, IT Alerting, Visual Command Center®, Crisis Commander®,
Community Engagement™ and Secure Messaging. Everbridge serves 9 of the
10 largest U.S. cities, 8 of the 10 largest U.S.-based investment banks,
25 of the 25 busiest North American airports, six of the 10 largest
global consulting firms, six of the 10 largest global auto makers, all
four of the largest global accounting firms, four of the 10 largest
U.S.-based health care providers and four of the 10 largest U.S.-based
health insurers. Everbridge is based in Boston and Los Angeles with
additional offices in San Francisco, Lansing, Orlando, Beijing, London,
and Stockholm For more information, visit www.everbridge.com
,
read the company blog
,
and follow on Twitter
and Facebook
.
Cautionary Language Concerning Forward-Looking Statements
This
press release contains “forward-looking statements” within the meaning
of the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including but not limited to, statements regarding
the anticipated opportunity and trends for growth in our critical
communications and enterprise safety applications and our overall
business, our market opportunity, our expectations regarding sales of
our products, and our goal to maintain market leadership and extend the
markets in which we compete for customers. These forward-looking
statements are made as of the date of this press release and were based
on current expectations, estimates, forecasts and projections as well as
the beliefs and assumptions of management. Words such as “expect,”
“anticipate,” “should,” “believe,” “target,” “project,” “goals,”
“estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,”
variations of these terms or the negative of these terms and similar
expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which involve factors or circumstances that are
beyond our control. Our actual results could differ materially from
those stated or implied in forward-looking statements due to a number of
factors, including but not limited to: our ability to successfully
integrate businesses and assets that we may acquire; the ability of our
products and services to perform as intended and meet our customers’
expectations; our ability to attract new customers and retain and
increase sales to existing customers; our ability to increase sales of
our Mass Notification application and/or ability to increase sales of
our other applications; developments in the market for targeted and
contextually relevant critical communications or the associated
regulatory environment; our estimates of market opportunity and
forecasts of market growth may prove to be inaccurate; we have not been
profitable on a consistent basis historically and may not achieve or
maintain profitability in the future; the lengthy and unpredictable
sales cycles for new customers; nature of our business exposes us to
inherent liability risks; our ability to attract, integrate and retain
qualified personnel; our ability to maintain successful relationships
with our channel partners and technology partners; our ability to manage
our growth effectively; our ability to respond to competitive pressures;
potential liability related to privacy and security of personally
identifiable information; our ability to protect our intellectual
property rights, and the other risks detailed in our risk factors
discussed in filings with the U.S. Securities and Exchange Commission
(“SEC”), including but not limited to our Annual Report on Form 10-K for
the year ended December 31, 2016 filed with the SEC on March 23, 2017.
The forward-looking statements included in this press release represent
our views as of the date of this press release. We undertake no
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this
press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410005436/en/
Contact:
Media Contact:
Everbridge
Jeff Young, 781-859-4116
jeff.young@everbridge.com
or
Investor
Contact:
ICR
Garo Toomajanian, 818-230-9712
ir@everbridge.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom